ACADIA Pharmaceuticals (ACAD) Projected to Post Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) is expected to be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect ACADIA Pharmaceuticals to post earnings of $0.13 per share and revenue of $273.04 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

ACADIA Pharmaceuticals Trading Down 2.4 %

NASDAQ:ACAD opened at $19.48 on Tuesday. ACADIA Pharmaceuticals has a twelve month low of $14.15 and a twelve month high of $26.56. The company has a market cap of $3.24 billion, a price-to-earnings ratio of 24.97 and a beta of 0.37. The stock has a fifty day simple moving average of $18.24 and a 200-day simple moving average of $16.75.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ACAD shares. Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $23.00 to $20.00 in a report on Friday, January 3rd. HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. StockNews.com downgraded ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft assumed coverage on ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “hold” rating and a $22.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $24.00.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.